Generic Medicine Info
Indications and Dosage
Plasma volume expander in hypovolaemic shock
Adult: Dose depends on preparation used. As 6% preparation: usual dose: 500-1000 ml; max dose: 2500 ml/day. As 10% preparation: usual dose range: 500-1000 ml; up to 1500 ml/day. Given as solution of normal saline or other electrolytes. The rate of infusion depends on the amount of fluid lost and degree of haemoconcentration; may be infuse up to 20 ml/kg/hr in acute haemolytic shock.
Infusion premixed in 0.9% sodium chloride.
Patients with severe heart failure, bleeding disorders such as hypofibrinogenaemia or thrombocytopenia or renal failure.
Special Precautions
Caution in patients with haemorrhage, cardiac disease, liver disease or renal impairment. Patients at risk of developing pulmonary oedema or heart failure. Monitor urine output. Monitor central venous pressure during the initial period of infusion to detect fluid overload. Avoid haematocrit concentration from falling <25-30%. Monitor patient for signs of hypersensitivity reactions. To stop infusion if there are signs of oliguria or renal failure. Monitor for early signs of bleeding complications. Monitor electrolytes. Should only be used in children under expert supervision.
Adverse Reactions
Transient increase in bleeding time may occur. Pruritus. May raise serum amylase. Fluid overload.
Potentially Fatal: Severe anaphylactic reactions.
Mechanism of Action: Pentastarch is a macromolecule that is used to expand and maintain blood volume in shock arising from conditions such as burns or septicaemia.
Duration: For 6%: 24-36 hr.
Distribution: Distributes into tissues; some may persist in body for several years.
Metabolism: Molecules with molecular wt <50000, excreted unchanged by kidney. Molecules with molecular wt >50000 are metabolised and excreted more slowly. Metabolism rate depends on size of molecule.
Excretion: Approx 33% of high molecular wt and approx 70% of medium molecular wt molecules are excreted via urine within 24 hr.
MIMS Class
Intravenous & Other Sterile Solutions
Disclaimer: This information is independently developed by MIMS based on Pentastarch from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in